Azura Ophthalmics   Report issue

For profit Phase 3
Founded: Tel Aviv Israel (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2018
NCT03652051
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Azura Ophthalmics

Active Ingredients

Drugs in Phase 3 Trials (1)

azr-md-001 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1